Figure 1.
Enrollment, Assignment and Follow-up of the patients that were included in this prospective comparison of combined navigated macula laser therapy and mono anti-VEGF therapy.
Table 1.
Baseline Characteristics of the Sample.
Figure 2.
Course of best-corrected visual acuity (BCVA) and central retinal thickness (CRT).
(A) Change in best-corrected visual acuity (BCVA) and (B) change in central retinal thickness (CRT) during 12 months follow-up (Error bars: 95% CI). Eyes received three Rbz loading injections and combination therapy eyes additionally received Navigated MLT 115±113 days mean from baseline. Thereafter, all eyes received PRN injections. Three months from baseline, combination therapy eyes had improved by a mean 7.9±7.6 letters and monotherapy eyes had improved by 5.5±5.8 letters (difference p = 0.150) and remained stable through the PRN phase. Twelve-month values were 8.4±8.3 letters and 6.3±6.5 letters, respectively (difference p = 0.258). Similarly, during 12 months CRT in the combination therapy cohort had improved by a mean -129±170 µm and in the monotherapy cohort from by a mean −105±107 µm (difference p = 0.487).
Figure 3.
Kaplan-Meier analysis of injection retreatment after the last loading phase injection.
A significantly higher proportion of Rbz monotherapy patients (84%) required injection retreatment compared to the navigated laser combination therapy cohort (35%, difference p≤0.001). Median time to retreatment was 63 and>300 days (median not reached during follow-up), respectively.
Table 2.
Best-Corrected Visual Acuity (BCVA) and Central Retinal Thickness (CRT) changes at month 12.
Table 3.
Analysis of required treatments.